Trade BeyondSpring Inc. - BYSI CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.0446
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021596 %(-$4.32)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02160%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000626 %(-$0.13)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00063%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021596 %
  (-$4.32)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000626 %
  (-$0.13)

Key Stats

• Prev. Close: 0.6031
• Open: 0.5957
• 1-Year Change: -66.81%
• Day's Range: 0.5876 - 0.6206

Trade BeyondSpring Inc. - BYSI

About Beyondspring Inc

BeyondSpring Inc. is a global biopharmaceutical company that is focused on developing immuno-oncology cancer therapies. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).

Financial summary

BRIEF: For the nine months ended 30 September 2021,Beyondspring Inc revenues increased from $0K to $1M. Netloss increased 26% to $54.7M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsGeneral and administrative - Balancing increase from $10.2Mto $22M (expense), Stock-based Compensation in SGA increaseof 76% to $3.7M (expense).